The DNA Resource Core was founded in 1999 and has been continuously funded by the CCSG as a DF/HCC Shared Resources since 2000. The facility is currently led by J. Wade Harper and is jointly managed (Cancer Center and Institution). The Core provides investigators access to specialized resources such as informatics support, rapid and user-friendly high-throughput DNA sequencing services and cDNA/RNAi clone repository and distribution services. The success of the DNA Resource Core is evidenced by its usage, sequencing about 200,000 samples per year. In 2004, the PlasmID DNA repository and associated in-house plasmid database was added. This repository's current collection includes more than 241,000 plasmid DNA clones useful for cloning, mutagenesis and expression relevant to more than 25 different species, with the emphasis on human cancer-related gene collections. In addition, based on the expressed need of DF/HCC members, the DNA Resource Core has now integrated shRNA libraries into the PlasmID DNA repository. Director: J. Wade Harper, PhD(HMS) Category: 1.2 (Molecular Biology) Management: Joint (Cancer Center and Institution).
The DNA Resource Core was created to address the sequencing needs of both small-and large-scale DNA sequencing users in DF/HCC. The Core's mission is to provide quality and priority access to specialized resources and services. These services constitute an integral component of the vast majority of basic and translational sciences being done under the umbrella of DF/HCC.
|Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :|
|Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8|
|Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52|
|Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8|
|Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504|
|Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96|
|McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534|
|Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201|
|Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46|
|Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381|
Showing the most recent 10 out of 303 publications